Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. FDX
4. CBRS
5. HTZ
6. USO
7. SPY
8. KBH
9. LAES
10. HON

Go back to Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
(NASDAQ: FULC) Delayed: 3.76 --0 (-0%)
Previous Close $3.76    52 Week High $ 
Open $3.76    52 Week Low $ 
Day High $3.76    P/E N/A 
Day Low $3.76    EPS $ 
Volume 45       

SANOFI (NASDAQ: SNY) Delayed: 41.33 --0 (-0%)
Previous Close $41.33    52 Week High $44.76 
Open $41.33    52 Week Low $36.81 
Day High $41.33    P/E N/A 
Day Low $41.33    EPS $0.00 
Volume 1,311